HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mary Anne Dellva Selected Research

Insulin Lispro (Humalog)

1/2022Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
1/2022Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
11/2021Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.
2/2021Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.
12/2020Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.
12/2020Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial.
10/2020Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
10/2020Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mary Anne Dellva Research Topics

Disease

6Major Depressive Disorder (Major Depressive Disorders)
05/2016 - 04/2010
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2022 - 10/2020
3Type 2 Diabetes Mellitus (MODY)
01/2022 - 12/2020
2Injection Site Reaction
02/2021 - 10/2020
2Nausea
01/2014 - 04/2010
2Psychotic Disorders (Schizoaffective Disorder)
04/2010 - 08/2007
2Schizophrenia (Dementia Praecox)
04/2010 - 08/2007
1Erectile Dysfunction
01/2014
1Pain (Aches)
01/2014
1Fatigue
01/2014
1Hyperhidrosis
01/2014
1Headache (Headaches)
04/2010
1Bipolar Disorder (Manic Depressive Psychosis)
04/2010
1Constipation
04/2010
1Dementia (Dementias)
04/2010
1Sleep Initiation and Maintenance Disorders (Insomnia)
04/2010
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
03/2007

Drug/Important Bio-Agent (IBA)

8Insulin Lispro (Humalog)FDA Link
01/2022 - 10/2020
6alpha- ((5- fluoro- 2- methoxyphenyl)methyl)- alpha- (tetrahydro- 2H- pyran- 4- yl)- 2- morpholinemethanolIBA
05/2016 - 04/2010
5Norepinephrine (Noradrenaline)FDA LinkGeneric
05/2016 - 04/2010
4Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
05/2016 - 01/2014
3Glucose (Dextrose)FDA LinkGeneric
01/2022 - 10/2020
2Antidepressive Agents (Antidepressants)IBA
06/2015 - 01/2015
1Olanzapine (Zyprexa)FDA Link
04/2010
1Antipsychotic Agents (Antipsychotics)IBA
08/2007
1Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric
03/2007

Therapy/Procedure

2Therapeutics
05/2016 - 06/2015
1Duration of Therapy
08/2007